nach oben

01.11.2003 | Original Article

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

verfasst von: Françoise Bouet-Toussaint, Jean-Jacques Patard, Alban Gervais, Noëlle Genetet, Cécile Thomas de la Pintière, Nathalie Rioux-Leclercq, Olivier Toutirais, Anne-Sophie Thirouard, Marie-Paule Ramée, Véronique Catros-Quemener

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2003

Einloggen, um Zugang zu erhalten

Abstract

Adoptive immunotherapy with antitumor effector cells is an attractive therapeutic approach in metastatic renal cell carcinoma (RCC). The aim of the work was to enhance in vitro activation of lymphocytes with optimal cytotoxic activity against tumor cells. We evaluated a procedure based on the use of dendritic cells (DCs) loaded with irradiated tumor cells (DC-Tu) to stimulate lymphocytes. Experimental conditions were established with cells from healthy donors and melanoma cell lines. Procedures were then applied to cells from RCC patients. A total of 30 tumor biopsies, 14 proximal lymph nodes, and 17 peripheral blood samples from 30 patients were used. When lymphocytes were stimulated in vitro with DC-Tu, they responded to tumor cells with an increased cytolytic activity for all the assays with donor cells (n=18). For RCC patients, DC-Tu stimulation improved the final cytotoxic activity in only half of the assays (16/31). When significantly enhanced (>10%, n=8), responder cells resulted in a final 43% cytotoxicity against autologous RCC cells. Mechanism of lysis was at least in part class I mediated. Effector cells have no lytic activity against normal renal cells. Percentage of cells with regulatory T-cell phenotype was not found to be enhanced in the DC-Tu stimulated lymphocytes. Individual differences were observed in the characteristics of DCs generated from RCC patients in contrast to that observed in donors and could explain why lymphocyte stimulation was not improved by DC-Tu in half of the RCC assays. T-cell spreading was suitable for a therapeutic use (>10⁹ cells) irrespective of the procedure (with or without DC-Tu stimulation) or the tissular origin of lymphocytes from patients. Data show that precursors of selective antitumor effector cells are present in patients with RCC and can be amplified in vitro either with or without DC-Tu stimulation. One of these populations could be chosen for an adoptive transfer immunotherapy.

Almand B, Clark JI et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689PubMed

Belldegrun A., W. Pierce et al (1993) Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma. J Urol 150:1384–1390PubMed

Bernhard H, Karbach J et al (1994) Cellular immune response to human rena-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 59:837–842PubMed

Boisteau O, Gautier F et al (1997) Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997:403–412

Bouet-Toussaint F, Genetet N et al (2000) Interleukin 2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokin Network 11(2):217–224

Caignard A, Guillard M et al (1996) In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 66:564–570CrossRefPubMed

Delneste Y, Magistrelli G et al (2002) Involvement of LOX-1 in dendritic cell mediated antigen cross-presentation. Immunity 17(3):353PubMed

Dudley M, Wunderlich J et al (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor-antigen specific T lymphocytes in patients with metastatic melanoma. J Immunother 25(3):243–51CrossRefPubMed

Figlin R, Pierce W et al (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J Urol 158:740–745PubMed

10.

Figlin RA, Thompson JA et al (1999) Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521–2529PubMed

11.

Finke JH, Rayman P et al (1992) Characterisation of a human renal cell carcinoma specific cytotoxic CD8⁺ T cell line. J Immunother 11:1–11PubMed

12.

Fuhrman SA, Lasky LC et al (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663PubMed

13.

Goey SH, Verweij J et al (1996) Immunotherapy of metastatic renal cell cancer. Annals of Oncology 7:887–900PubMed

14.

Groh V, Rhinehart R et al (2001) Costimulation of CD8αβTcells by NKG2D via engagement by MIC induced on virus-infected cells. Nature Immunology 2:255–260CrossRefPubMed

15.

Guinan P, Sobin LH et al (1997) TNM staging of renal cell carcinoma: workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80(5): 992–993CrossRefPubMed

16.

Hänninen EL, Kirchner H et al (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155:19–25PubMed

17.

Hayakawa M, Hatano T et al (1994) Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2. Urol Int 53:117–124PubMed

18.

Hoffmann T, Meidenbauer N et al (2000) Generation of tumor-specific T-lymphocytes by cross-priming human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60(13):3542–3549PubMed

19.

Jonuleit H, Schmitt E et al (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in immunology 22(7):394–400CrossRefPubMed

20.

Jotereau F, Pandolfino MC et al (1991) High fold expansion of human cytotoxic t-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10:405–411PubMed

21.

Kugler A, Stuhler G et al (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6(3):332–336PubMed

22.

Liau LM, Black KL et al (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124PubMed

23.

Mathiot C, Thiounn N et al (1995) Non-cytotoxic CD4 Tumour-infiltrating lymphocytes induce responses in patients with metastatic renal cell carcinoma previously treated with interleukin-2. Eur J Cancer 31A(9):1552–1553PubMed

24.

Menetrier-Caux C, Thomachot M et al (2001) IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res 61(7):3096–3104PubMed

25.

Motzer RJ, Mazumdar M et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540PubMed

26.

Mulders P, Tso C-L et al (1999) Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 5:445–454PubMed

27.

Negrier S, Escudier B et al (1998) Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272–1278CrossRefPubMed

28.

Nestlé FO, Alijagic S et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332PubMed

29.

Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179(4):1109–1118PubMed

30.

Thurnher M, Radamyr C et al (1996) Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68:1–7PubMed

31.

Weng NP, Levine BL et al (1995) Human naive and memory T lymphocytes differ in telomeric lenght and replicative potential. Proc Natl Acad Sci USA 92:11091–11094PubMed

Titel: Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use
verfasst von: Françoise Bouet-Toussaint
Jean-Jacques Patard
Alban Gervais
Noëlle Genetet
Cécile Thomas de la Pintière
Nathalie Rioux-Leclercq
Olivier Toutirais
Anne-Sophie Thirouard
Marie-Paule Ramée
Véronique Catros-Quemener
Publikationsdatum: 01.11.2003
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 11/2003
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0412-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie